DoH Partners With Gilead Sciences To Enhance Healthcare Innovation And Cell Therapy Access

The Department of Health – Abu Dhabi (DoH) has entered into two Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical firm. This collaboration, announced during the Abu Dhabi Global Healthcare Week 2025, aims to enhance clinical research and healthcare accessibility. The agreements focus on improving treatment options and fostering medical innovation within the emirate.

The MoUs were signed by Dr. Asma Ibrahim Al Mannaei from DoH and Vitor Papao from Gilead Sciences. Dr. Noura Khamis Al Ghaithi, Under-Secretary of DoH, was present at the signing. These agreements aim to position Abu Dhabi as a leader in medical research by focusing on virology and cell therapies. The partnership seeks to expand access to advanced treatments and improve healthcare outcomes for local communities.

Dr. Asma Ibrahim Al Mannaei stated, "Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities." She emphasised that these efforts align with Abu Dhabi's vision for a smart healthcare system, aiming to provide tools for maintaining healthy populations.

Vitor Papao highlighted the importance of these MoUs in supporting Abu Dhabi's vision for medical research excellence. He said, "These MoUs reaffirm Gilead and Kite’s commitment to healthcare innovation and underscore our contribution to the healthcare ecosystem in Abu Dhabi." Papao noted that this collaboration aligns with national goals to strengthen healthcare systems and expand access to transformative treatments like CAR T-cell therapies.

Abu Dhabi is committed to integrating cutting-edge medical technologies through strategic collaborations like this one. These efforts ensure that the emirate remains a hub for world-class healthcare practices. By enhancing research capabilities, Abu Dhabi aims to maintain its status as a model for healthcare excellence globally.

The partnership between DoH and Gilead Sciences reflects Abu Dhabi's dedication to advancing its healthcare sector. By focusing on innovative therapies and research, they aim to deliver top-tier care both locally and beyond. This collaboration is expected to drive significant advancements in medical research and treatment accessibility in the region.

In summary, these agreements highlight Abu Dhabi's ongoing efforts to lead in healthcare innovation. Through strategic partnerships, they aim to enhance their capacity for delivering exceptional care while supporting sustainable health advancements for future generations.

With inputs from WAM